Indaptus Therapeutics Inc. is a pioneering biotechnology firm focused on advancing immunotherapies that aim to transform cancer treatment paradigms. Utilizing its proprietary platform, the company enhances the immune system's capacity to identify and eliminate tumor cells, thereby improving therapeutic efficacy and patient outcomes. With a robust pipeline of clinical candidates aimed at addressing critical unmet needs in oncology, Indaptus is strategically positioned for growth in a competitive market. By fostering collaborations with leading research institutions and a commitment to scientific innovation, Indaptus aspires to emerge as a key player in the biopharmaceutical sector.
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | 0 |
| EBITDA | $-19.83M |
| Operating Margin | 0.00% |
| Return on Equity | -932.00% |
| Return on Assets | -286.80% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $0.01 |
| Price-to-Book | 329.41 |
| Price-to-Sales (TTM) | — |
| EV/Revenue | - |
| EV/EBITDA | 1.03 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $133.24M |
| Float | $3.24M |
| % Insiders | 96.93% |
| % Institutions | 0.08% |
STAMFORD, Conn., June 17, 2026 (GLOBE NEWSWIRE) -- Abbott Cooper PLLC is investigating potential legal claims on behalf of stockholders of Indaptus Therapeutics, Inc. (Nasdaq: INDP) who held their shares prior to December 22, 2025.
NEW YORK, May 15, 2026 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) (“Indaptus” or the “Company”), a clinical-stage biotechnology company, today announced financial results for the first quarter ended March 31, 2026, and provided a strategic corporate update. Junyi Dai, Indaptus Therapeutics' Chief Executive Officer and Chairman of the Board, commented, “Following recent changes in executive management, the Company has conducted a review of its development programs, operating resources and ongoing corporate initiatives.
